B4GALNT2 knock out pig
AssigneeMayo Foundation for Medical Education and Research
InventorsChristopher G. A. McGregor, Guerard W. Byrne
Life of this patent
Estimating the term…
Abstract
This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine β1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous α-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.
Claims1
A transgenic pig whose genome comprises a homozygous disruption of the endogenous βi, 4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) nucleic acid, wherein the pig does not express functional B4GALNT2 polypeptide having the amino acid sequence as set forth in SEQ ID NO:
- 1, and wherein the pig exhibits no expression of Sda or SDa-like glycans in the somatic cells as compared to a control non-transgenic pig.
Dependencies are inferred from the claim text.